摘要
目的探讨脑膜瘤中整合素α3及Ki-67的表达及其生物学意义。方法用免疫组化方法检测43例脑膜瘤、5例正常硬脑膜及5例蛛网膜中整合素α3及Ki-67的表达。结果在WHOⅠ级及WHOⅡ、Ⅲ级脑膜瘤中,整合素α3的阳性表达率分别为80.0%(28/35)及37.5%(3/8),χ2=4.133,P=0.021;Ki-67标记指数分别为(2.24±0.84)%及(10.20±2.11)%,t=10.468,P=0.000,其差异均有统计学意义;且整合素α3的表达与Ki-67标记指数具有负相关关系,r=-0.89,P=0.000。结论整合素α3表达下调能促进脑膜瘤细胞的增殖及侵袭;整合素α3与Ki-67的表达均可应用于临床;作为评价脑膜瘤恶性程度、选择治疗措施及预测患者预后等的有力指标。
Objective To investigate the expressions of integrin α3 and Ki-67 antigens in meningiomas and their biological significance. Methods Immunohistochemical assay was used to determine the expressions of integrin α3 and Ki-67 antigen in meningiomas （43 cases）, normal brain tissues （5 cases） and arachnoid tissues （5 cases）. Results In meningiomas of grade Ⅰ and grade Ⅱ Ⅲ, the positive expression rates of integrin α3 were 80.0 % （28/35）, 37.5 % （3/8）, respectively, χ^2 = 3.924, P = 0.028; the Ki-67 labeling index were （2.24±0.84）%, （10.20±2.11 ）%, respectively, t = 10.468, P = 0.000. The differences were statistical significance. Moreover, there was a negative correlation between the expression of integrin α3 and Ki-67 labeling index, r = -0.89, P = 0.000. Conclusion The down-regulating expression of integrin α3 in meningiomas promotes proliferation and invasion of meningioma cells. The expressions of integrin α3 and Ki-67 can be applied as a cogent indicator clinically to judge the malignant grade of human meningiomas, to select treatment strategies, and to predict proguoses of the patients.
出处
《四川医学》
CAS
2006年第10期1005-1006,共2页
Sichuan Medical Journal
